About
IDT Biologika

Our clinical and commercial manufacturing is located in Dessau, Germany. At our Magdeburg site is our R&D Center, which specializes in process development and analytical services.

Our excellent track record is manifested by successful inspections and approvals from major regulatory agencies including FDA, EMA and ANVISA.

In response to the rapid growth and demand in Advanced Therapies, we also support the development and manufacturing of viral vectors for cell and gene therapeutics and are proud to be one of the first suppliers for commercial manufacturing of an oncolytic virus product, worldwide.

Our innovation, outstanding technological expertise and process excellence brings us to delivering for commercial programs for over three decades by providing liquid and lyophilized fill-finish of vaccines and other biologics, such as monoclonal antibodies and recombinant proteins. IDT Biologika has spent a century committed to the protection and improvement of human health worldwide, and our experienced international team is dedicated to continue this effort into the future.

In 2021, IDT Biologika reached the landmark of 100 years working in the development and manufacture of vaccines that protect humans all around the world. We continually put this unparalleled experience to work for our customers and in the last two decades have been involved in development and production of vaccines against infectious diseases such as COVID-19, influenza, smallpox, AIDS, malaria, Ebola, Chikungunya, Lassa fever, and Dengue fever. IDT Biologika has also worked on the production of vaccines against certain cancers. Our vision is to remain at the forefront of vaccines that offer critical protection to patient populations worldwide and continue to pioneer vital treatments for the next century.

IDT Biologika is a global biologics manufacturing organization, and we meet the needs of multinational customers and pharma companies around the world with manufacturing capabilities in Europe. The sites support our fully integrated services and are cGMP and BSL-2 -compliant, with approvals from the FDA, EMA, and ANVISA.

At IDT Biologika, we recognize how critical vaccines and novel therapeutics are to protecting and improving quality of life for patients around the world. This is the inspiration for investment and growth of our business. We continue to expand our operations, focused on delivering the highest quality end-to-end services with the ability to scale projects from development and preclinical volumes through to large-scale production and commercial packaging and supply. As part of a €114 million expansion, we created additional capacities in drug substance manufacturing, aseptic fill-finish, and visual inspection, which have been in operation since the end of 2022. Everything we do is underscored by our commitment to quality and operational excellence.